Korea Biopharmaceutical Industry Overview: K-Pharma Under the Global Spotlight
Korea's biopharmaceutical industry has undergone explosive growth over the past decade, emerging as the next-generation export flagship sector after semiconductors and automobiles. As of 2025, biopharmaceutical exports have surpassed approximately $13B, and Korean companies hold roughly 45% of the global biosimilar market.
Korean biotech companies — including BioTech Korea, Celltrion, and 코리아SK Bioscience — have secured unrivaled competitive positions in the global CDMO (Contract Development and Manufacturing) and biosimilar markets. Technology cooperation opportunities with the South Asian pharmaceutical market, particularly Bangladesh, are expanding rapidly, generating growing interest in synergies between the pharmaceutical industries of the two countries.
Biosimilars: Where Korea Leads the World
A biosimilar is a biologic medicine developed to be equivalent in efficacy and safety to an original biologic drug once its patent expires. Korea has been a pioneer in the global biosimilar market since Celltrion's Remsima (infliximab biosimilar) opened the field.
As of 2025, Korean companies have received FDA approval for more than 18 biosimilars and EMA (European Medicines Agency) approval for 22 products. In the monoclonal antibody (mAb) biosimilar segment in particular, Korean companies are evaluated at the global apex for technical capability.
| Rank | Company | Core Business | Revenue (2024) | Global Reach |
|---|---|---|---|---|
| 1 | BioTech Korea | CDMO and biosimilar | $3.3B | FDA/EMA approval |
| 2 | Celltrion | Biosimilar | $2.7B | FDA/EMA, 35 countries |
| 3 | 코리아SK Bioscience | Vaccine and CDMO | $850M | WHO PQ holder |
| 4 | Hanmi Pharmaceutical | New drug R&D (NASH) | $620M | FDA Phase 3 trial |
| 5 | Yuhan Corporation | Oncology new drug | $580M | 1 FDA approval |
| 6 | Korea Construction Cng Pharmaceutical | Botox and bio | $450M | Export to 60 countries |
| 7 | GC Pharma (Green Cross) | Blood products and vaccine | $420M | WHO PQ holder |
| 8 | Chong Kun Dang | Generic and bio | $380M | Asia expansion |
| 9 | HK Inno.N | GI new drug | $320M | FDA trial in progress |
| 10 | Genexine | Immuno-oncology | $150M | Multiple global trials |
Osong Bio Valley: The Heart of K-Bio
Located in Osong, North Chungcheong Province, the Osong Bio Valley is the core cluster of Korea's biopharmaceutical industry. Major regulatory bodies including the Ministry of Food and Drug Safety and the Korea Disease Control and Prevention Agency colocate with 120+ bio companies, creating a one-stop ecosystem spanning R&D, regulatory approval, and production.
The government is strategically developing five national bio clusters — Osong, Incheon Songdo, Daejeon, Wonju, and Gimhae — with a target of breaking into the global top five bio nations by 2030. The "K-Bio Global Hub Strategy" announced in 2024 reinforces foreign pharmaceutical company attraction and the global clinical trial support framework.
Korea vs. Bangladesh Pharmaceutical Industry Comparison
Korea and Bangladesh occupy complementary positions in the pharmaceutical industry. Korea holds strengths in biopharmaceutical and new drug R&D, while Bangladesh is competitive in high-volume generic drug manufacturing and low-cost drug supply leveraging its LDC TRIPs exemption. Bangladesh's major pharmaceutical companies — Square, Beximco, and Incepta — are pursuing WHO Prequalification (PQ), and in this process, demand for Korean GMP consulting and quality management expertise is high.
Cooperation Opportunities Between the Two Industries
Bangladesh can produce generics of patented drugs under TRIPs (Trade-Related Intellectual Property Rights) exemption provisions until 2032. This creates technology transfer, licensing, and joint venture opportunities for Korean bio companies. Bangladesh's largest pharmaceutical companies — Square, Beximco, and Incepta — are pursuing WHO Prequalification, and demand for Korean GMP consulting and quality management technology in support of this goal is substantial.
Market Outlook and Investment Focal Points
The global biopharmaceutical market is projected to grow at a CAGR of 12.5% through 2030, reaching approximately $850B. Korea maintains its position as the global #3 in CDMO and #1 in biosimilars, and the international brand recognition of K-Pharma is rising rapidly.
| Item | 2024 | 2027 (E) | 2030 (E) |
|---|---|---|---|
| Global Market Size | $480B | $620B | $850B |
| Biosimilar Market | $42B | $75B | $120B |
| CDMO Market | $25B | $38B | $52B |
| Korea Export Value | $11B | $17B | $25B |
| Korea-Bangladesh Cooperation Scale | $50M | $200M (E) | $500M (E) |
K-Pharma's global expansion is still in its early stages. When Korea's biotechnology capabilities meet Bangladesh's manufacturing base and regulatory advantages, a new value chain can form in the South Asian biopharmaceutical market. Systematic partner identification through the KOTRA Dhaka Trade Office and BIDA is the first step.